Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks.
Arch Dermatol
; 137(12): 1597-604, 2001 Dec.
Article
en En
| MEDLINE
| ID: mdl-11735710
ABSTRACT
OBJECTIVE:
To assess the safety and efficacy of 4 concentrations of tazarotene cream in the treatment of facial photodamage.DESIGN:
Prospective weekly multicenter, investigator-masked, randomized, parallel-group study.SETTING:
University hospitals and clinical research centers. PATIENTS Three hundred forty-nine subjects with facial photodamage. INTERVENTION Daily topical application of tazarotene cream (0.01%, 0.025%, 0.05%, and 0.1%) compared with its vehicle and with 0.05% tretinoin emollient cream.RESULTS:
Tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. At week 24, treatment success rates based on global responses were 67% (39 of 58 subjects) with 0.1% tazarotene, 52% (30 of 58 subjects) with 0.05% tazarotene, 36% (21 of 58 subjects) with 0.025% tazarotene, 41% (24 of 59 subjects) with 0.01% tazarotene, 55% (32 of 58 subjects) with 0.05% tretinoin, and 22% (13 of 58 subjects) with vehicle. Local adverse events, although more frequent with tazarotene at higher concentrations, were generally mild to moderate.CONCLUSIONS:
Tazarotene in a cream formulation is safe and is associated with positive changes in the treatment of photodamaged facial skin.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Retinoides
/
Envejecimiento de la Piel
/
Hiperpigmentación
/
Fármacos Dermatológicos
/
Ácidos Nicotínicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Arch Dermatol
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos